rev:    January 17, 2005

HOME (home page)

Return  (viral antigen.index)

  VIRAL ANTIGENS/Pure Proteins 

(for in vitro research use only)

RDI Divison of researchd Industries Intl  offers a wide line of  antigens for use in histochemistry, ELISA, and further manufacturing use. Please inquire for other antigens or antibodies to use with these products. Please inquire for Bulk quantities-significant discounts available!

-also new natural isolates for CMV IgG and IgM assays

    -$250.00/100ug   $625.00/0.5mg    $1125.0/1mg   Bulk quotes on request

RDI-CMV 211AG   Recombinant Cytomegalo Virus gB (11-76 a.a.)

RDI-CMV212AG    Recombinant Cytomegalo Virus pP28 (UL99) (130-160 a.a.)

RDI-CMV213AG    Recombinant Cytomegalo Virus Pp38 (UL80a) (117-373 a.a.)

RDI-CMV214AG    Recombinant Cytomegalo Virus pP52 (UL44) (202-434 a.a.)

RDI-CMV215AG    Recombinant Cytomegalo Virus pP65(UL83) (297-510 a.a.), 52,282 Dalton

RDI-CMV216AG    Recombinant Cytomegalo Virus pP150(UL32) (1011-1048 a.a.)

Cat# RDI-CMV211AG     $625.00/500 �g

PRODUCT  DESCRIPTION: E.coli derived recombinant.

The protein contains the CMV gB immunodominant regions.

PURIFICATION METHOD: Purified by proprietary chromatographic technique.

PURITY: Protein is >95% pure as determined by 10% PAGE (coomassie staining).

PROTEIN CONC: 1mg/ml in 25mM Tris-Hcl pH 8.0, 1mM EDTA and 50% glycerol.

STORAGE: Protein is shipped at ambient temperature. Upon arrival, Store at -20 DEG C.

STABILITY: Five years frozen. One month in solution at room temperature.

SPECIFICITY: Immunoreactive with sera of CMV-infected individuals.

APPLICATIONS: Antigen in ELISA and Western blots, excellent antigen for detection of CMV with minimal specificity problems.

Precautions: For In vitro research Use Only. Not for use in or on humans or animals or for diagnostics.  It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. We are not responsible for any patent infringements that might result with the use of or derivation of this product.

Cat# RDI-CMV212AG  

PRODUCT DESCRIPTION: E.coli derived recombinant.

The protein contains the CMV Pp28(UL99) immunodominant regions.

PURIFICATION METHOD: Purified by proprietary chromatographic technique.

PURITY: Protein is >95% pure as determined by 10% PAGE (coomassie staining).

PROTEIN CONC: 1mg/ml in 25mM Tris-Hcl pH 8.0, 1mM EDTA and 50% glycerol.

STORAGE: Protein is shipped at ambient temperature. Upon arrival, Store at -200C.

STABILITY: Five years frozen. One month in solution at room temperature.

SPECIFICITY: Immunoreactive with sera of CMV-infected individuals.

APPLICATIONS: Antigen in ELISA and Western blots, excellent antigen for detection of CMV with minimal specificity problems.

Precautions: For In vitro research Use Only. Not for use in or on humans or animals or for diagnostics.  It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. We are not responsible for any patent infringements that might result with the use of or derivation of this product.

Cat# RDI-CMV213AG  

PRODUCT DESCRIPTION: E.coli derived recombinant.

The protein contains the CMV Pp38(UL80a) immunodominant regions.

PURIFICATION METHOD: Purified by proprietary chromatographic technique.

PURITY: Protein is >95% pure as determined by 10% PAGE (coomassie staining).

PROTEIN CONC: 1mg/ml in 25mM Tris-Hcl pH 8.0, 1mM EDTA and 50% glycerol.

STORAGE: Protein is shipped at ambient temperature. Upon arrival, Store at -200C.

STABILITY: Five years frozen. One month in solution at room temperature.

SPECIFICITY: Immunoreactive with sera of CMV-infected individuals.

APPLICATIONS: Antigen in ELISA and Western blots, excellent antigen for detection of CMV with minimal specificity problems.

Precautions: For In vitro research Use Only. Not for use in or on humans or animals or for diagnostics.  It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. We are not responsible for any patent infringements that might result with the use of or derivation of this product.

Cat# RDI-CMV214AG  

PRODUCT DESCRIPTION: E.coli derived recombinant.

The protein contains the CMV Pp52 (UL44) immunodominant regions.

PURIFICATION METHOD: Purified by proprietary chromatographic technique.

PURITY: Protein is >95% pure as determined by 10% PAGE (coomassie staining).

PROTEIN CONC: 1mg/ml in 25mM Tris-Hcl pH 8.0, 1mM EDTA and 50% glycerol.

STORAGE: Protein is shipped at ambient temperature. Upon arrival, Store at -200C.

STABILITY: Five years frozen. One month in solution at room temperature.

SPECIFICITY: Immunoreactive with sera of CMV-infected individuals.

APPLICATIONS: Antigen in ELISA and Western blots, excellent antigen for detection of CMV with minimal specificity problems.

Precautions: For In vitro research Use Only. Not for use in or on humans or animals or for diagnostics.  It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. We are not responsible for any patent infringements that might result with the use of or derivation of this product.

Cat# RDI-CMV215AG  

PRODUCT DESCRIPTION: E.coli derived recombinant.

The protein contains the CMV Pp65(UL83) immunodominant regions.

QUANTITY: 1mg

LOT#:

PURIFICATION METHOD: Purified by proprietary chromatographic technique.

PURITY: Protein is >95% pure as determined by 10% PAGE (coomassie staining).

PROTEIN CONC: 1mg/ml in 25mM Tris-Hcl pH 8.0, 1mM EDTA and 50% glycerol.

STORAGE: Protein is shipped at ambient temperature. Upon arrival, Store at -200C.

STABILITY: Five years frozen. One month in solution at room temperature.

SPECIFICITY: Immunoreactive with sera of CMV-infected individuals.

APPLICATIONS: Antigen in ELISA and Western blots, excellent antigen for detection of CMV with minimal specificity problems.

Precautions: For In vitro research Use Only. Not for use in or on humans or animals or for diagnostics.  It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. We are not responsible for any patent infringements that might result with the use of or derivation of this product.

Cat# RDI-CMV216AG

PRODUCT DESCRIPTION: E.coli derived recombinant.

The protein contains the CMV Pp150 (UL32) immunodominant regions.

PURIFICATION METHOD: Purified by proprietary chromatographic technique.

PURITY: Protein is >95% pure as determined by 10% PAGE (coomassie staining).

PROTEIN CONC: 1mg/ml in 25mM Tris-Hcl pH 8.0, 1mM EDTA and 50% glycerol.

STORAGE: Protein is shipped at ambient temperature. Upon arrival, Store at -200C.

STABILITY: Five years frozen. One month in solution at room temperature.

SPECIFICITY: Immunoreactive with sera of CMV-infected individuals.

APPLICATIONS: Antigen in ELISA and Western blots, excellent antigen for detection of CMV with minimal specificity problems.

Precautions: For In vitro research Use Only. Not for use in or on humans or animals or for diagnostics.  It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. We are not responsible for any patent infringements that might result with the use of or derivation of this product.

cat#RDI-CMVGSOL-AG   $312.00/1ml  + $125/ml 2 or more   $1562.00/10ml Bulk quotes on request

      Viral Strain: AD169 from ATCC, propagated in HF Cells , packaged in  0.1 M Glycine, pH 9.5 +/- 0.2

     approx  0.15 - 0.25 mg/ml (<10% Viral Protein) see batch sheet for batch specific information Store -70 DEG C

    -recommended for IgG antibody detection

cat#RDI-CMVMSOL-AG    $312.00/1ml  + $125/ml 2 or more  $1562.00/10ml Bulk quotes on request

      Viral Strain: AD169 from ATCC, propagated in HF Cells , packaged in  0.1 M Glycine, pH 9.5 +/- 0.2

     approx  0.25 - 0.35 mg/ml (<10% Viral Protein) see batch sheet for batch specific information Store -70 DEG C

     -recommended for IgM antibody detection

Custom Packaging is available

Quality Control involves coating ELISA plates and assaying a series of panel samples. Reactivity to the negative control must not be more than twice the blank. Infectivity Analysis: Negative infectivity for CMV is defined as the inability of an inactivated virus preparation to produce CPE after eighteen (18) days of incubation on a monolayer of HF cells.

Cytomegalovirus (CMV) is considered one of the most common viral infections in man. The virus rarely causes disease, but may persist as a latent or chronic infection of the salivary glands, renal tubules, cervix and leukocytes. The incidence and spectrum of the disease in newborns and immunocompromised hosts establish the virus as an important human pathogen. CMV infections are frequent and occasionally severe in children or adults with congenital or acquired defects of cellular immunity, such as patients with AIDS, cancer patients, and recipients of organ transplants. The transmission of CMV via transfused blood may account for most CMV infections in organ transplant recipients, neonates, and heart surgery patients. Medical conditions caused by CMV include: interstitial pneumonia, mononucleosis (heterophile negative), congenital defects, abortion, mental retardation, blindness and deafness.

Serological tests for the detection and quantification of antibodies to CMV are a valuable aid in diagnosing primary infection. Serology represents the only practical system at present for screening blood and organ donors and recipients to prevent the transmission of latent CMV to patients at high risk for severe CMV disease.

Cytomegalovirus Antigens are prepared by proprietary glycine extraction of human fibroblast cells infected with cytomegalovirus, strain AD 169 (ATCC). The CMV-M extraction procedure differs from the CMV-G procedure; it is designed to increase the relative amount of early viral CMV antigens. Both antigen preparations are partially purified to reduce host cell components prior to inactivation with UV light. The CMV-G & CMV-M antigens have yielded lot-to-lot consistency in IgG & IgM ELISA tests respectively, providing high sensitivity and low backgrounds.

Higher antibody reactivity is achieved with lower total protein for both the CMV-G and CMV-M products as compared to two commercial products. The higher specific activity achieved through partial purification of the CMV antigens assures improved sensitivity and specificity for your assays.

San Jose, 95123 CA Snell ave 658

USA

or 408-780-0908

EMAIL:margaret@cellular-research.com

Return  (viral antigen.index)

Ordering terms